Iodixanol Pharmacokinetics in Children

Johnson, Walter H.; Lloyd, Thomas R.; Victorica, Benjamin E.; Zales, Vincent R.; Epstein, M. A.; Leff, Richard D.; Ardinger, Robert H.; Slovis, T. L.; Johnson, Judith A.; Marsters, P

doi:10.1007/s002460010208

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that the highest iodixanol concentration in peripheral circulation is in the range of 0.97‐11 mg/mL, with a median of 4.7 mg mL −1 after its intravascular injection at clinically allowable doses. [ 25 ] Considering further dilution of slowly released iodixanol from our BRS under blood circulation, we expect thousand‐fold reductions in iodixanol concentration in blood flow resulting from BRS as compared to angiography in current clinical practice. Therefore, we do not anticipate any issue with the in vivo biocompatibility of our radiopaque BRS.…”

Section: Resultsmentioning

confidence: 99%

3D‐Printed Radiopaque Bioresorbable Stents to Improve Device Visualization

Ding

Collins

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Bioresorbable stents (BRS) hold great promise for the treatment of many life‐threatening luminal diseases. Tracking and monitoring of stents in vivo is critical for avoiding their malposition and inadequate expansion, which often leads to complications and stent failure. However, obtaining high X‐ray visibility of polymeric BRS has been challenging because of their intrinsic radiolucency. This study demonstrates the use of photopolymerization‐based 3D printing technique to fabricate radiopaque BRS by incorporating iodixanol, a clinical contrast agent, into a bioresorbable citrate‐based polymer ink. The successful volumetric dispersion of the iodixanol through the 3D‐printing process confers strong X‐ray visibility of the produced BRS. Following in vitro degradation, the 3D‐printed BRS embedded in chicken muscle maintains high X‐ray visibility for at least 4 weeks. Importantly, the 3D‐printed radiopaque BRS demonstrates good cytocompatibility and strong mechanical competence in crimping and expansion, which is essential for minimally invasive stent deployment. In addition, it is found that higher loading concentrations of iodixanol, e.g. 10 wt.%, results in more strut fractures in stent crimping and expansion. To conclude, this study introduces a facile strategy to fabricate radiopaque BRS through the incorporation of iodixanol in the 3D printing process, which could potentially increase the clinical success of BRS.

show abstract

Section: Resultsmentioning

confidence: 99%

3D‐Printed Radiopaque Bioresorbable Stents to Improve Device Visualization

Ding

Collins

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…However, some drugs are known to exhibit agedependent pharmacokinetics. 2,3) In cases where the pharmacokinetics are represented as plasma clearance 4) or elimination half-life 5) and the disposition is age-related, direct application of the dosing regimen for adults to children with only consideration of body weight is inadequate. Therefore to assess age-related pharmacokinetics, is important and helpful to optimize the dosage regimen for children.…”

mentioning

confidence: 99%

Linear Pharmacokinetics of Micafungin and Its Active Metabolites in Japanese Pediatric Patients with Fungal Infections

Tabata

Katashima

Kawamura

et al. 2006

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Development of novel medical products labeled for pediatric use is limited because it is difficult to obtain the safety and pharmacological effect data for the population at the time of approval. The International Conference on Harmonization has issued guidance E11 'clinical investigation of medical products in the pediatric population' to encourage this development. 1) In general, the dosing recommendations for pediatric patients are based on a milligrams per kilogram body weight. However, some drugs are known to exhibit agedependent pharmacokinetics. 2,3) In cases where the pharmacokinetics are represented as plasma clearance 4) or elimination half-life 5) and the disposition is age-related, direct application of the dosing regimen for adults to children with only consideration of body weight is inadequate. Therefore to assess age-related pharmacokinetics, is important and helpful to optimize the dosage regimen for children.Micafungin sodium, a new injectable anti-fungal drug classified as an echinocandin, [6][7][8][9] was first launched in Japan as Fungard TM for the treatment of deep-seated fungal infections such as Candidiasis and Aspergillosis. It was then also approved as Mycamine TM by the US Food and Drug Administration in March 2005 for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and treatment for esophageal candidiasis.10)The pharmacokinetics of micafungin have been investigated in healthy adults, [11][12][13] adult patients undergoing a bone marrow or peripheral stem cell transplant, 14) febrile neutropenic pediatric patients, 15) volunteers with moderate liver disease and renal dysfunction, 16) and a study of drug-drug interaction with Tacrolimus. 17) In Japan, four phase I studies and one Phase II study in adult patients with fungal infections were conducted. Micafungin appeared to be well tolerated, and showed linear pharmacokinetics over the dose range of 2.5 to 150 mg/d (0.5-4.0 mg/kg in children). That is, the maximum plasma concentration of micafungin increased in proportion to the dose, 20) and the elimination half-life (t 1/2 ) was constant for the doses investigated at 13.5Ϯ3.1 h (meanϮS.D., nϭ95). The metabolites of micafungin, M1 (catechol form) and M2 (methoxy form), have comparable pharmacologically active in the experimental infection model, 18) and were detected in the plasma in the steady state after administration to the patient. However the plasma concentrations of M1 and M2 at the dose of 150 mg were very low compared with that of unchanged drug. 11)Thus, while the pharmacokinetics of micafungin and its metabolites in adults has been sufficiently investigated, the pediatric pharmacokinetics remain unclear. In this article, the pharmacokinetic analyses of micafungin and its metabolites in Japanese pediatric patients with fungal infections are described, and their dose-linear pharmacokinetic and age-related pharmacokinetic properties are clarified. The optimal dosage for pediatric use is also proposed herein. MATERIALS AND MET...

show abstract

Chemistry, Physicochemical Properties and Pharmacokinetics of Iodinated Contrast Agents

Erol

Yiğitaslan

2021

Medical Imaging Contrast Agents: A Clinical Manual

View full text Add to dashboard Cite

Iodixanol Pharmacokinetics in Children

Cited by 7 publications

References 11 publications

3D‐Printed Radiopaque Bioresorbable Stents to Improve Device Visualization

3D‐Printed Radiopaque Bioresorbable Stents to Improve Device Visualization

Linear Pharmacokinetics of Micafungin and Its Active Metabolites in Japanese Pediatric Patients with Fungal Infections

Chemistry, Physicochemical Properties and Pharmacokinetics of Iodinated Contrast Agents

Contact Info

Product

Resources

About